Summary & Overview
HCPCS J0208: Sodium Thiosulfate (Pedmark) Injection, 100 mg
HCPCS Level II code J0208 denotes the injectable formulation sodium thiosulfate (Pedmark), 100 mg, used primarily as a protective adjunct in oncology care. This national-level billing code captures a specialty infused medication administered in outpatient infusion centers, hospital outpatient departments, and clinic-based infusion suites. Its relevance stems from specialty drug pricing, coding consistency for oncology adjunct therapies, and payer coverage policies that affect patient access to protective agents during chemotherapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical purpose, common sites of service, and the payer landscape impacting coverage and prior authorization practices. The publication also outlines billing considerations such as service-line placement and commonly reported modifiers where available, and presents benchmarking context for utilization and claim-processing practices.
This piece is intended for revenue-cycle professionals, oncology pharmacists, and policy analysts seeking a clear reference on coding and payer considerations for HCPCS Level II code J0208. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0208 describes Injection, sodium thiosulfate (Pedmark), 100 mg. This billing code represents administration of sodium thiosulfate formulated as Pedmark, typically used as a protective agent in oncology settings. Service type: injectable drug administration. Typical site of service: hospital outpatient infusion center or clinic-based infusion suite.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J0208 (Injection, sodium thiosulfate (Pedmark), 100 mg) is an adult or pediatric oncology patient undergoing systemic chemotherapy with cisplatin who requires sodium thiosulfate for otoprotection or as a chemoprotectant during high-dose platinum therapy. The clinical workflow: patient arrives to the outpatient infusion center or hospital infusion clinic, verification of chemotherapy orders and consent is completed by the oncology RN or pharmacist, baseline hearing assessment or relevant labs reviewed, and J0208 is prepared by the pharmacy in accordance with weight-based dosing. The medication is administered intravenously as a timed infusion relative to cisplatin per protocol. Nursing documents lot numbers, route, dose, start and stop times, and monitors for adverse reactions. Billing for J0208 is submitted per vial unit (100 mg) with the applicable HCPCS modifiers to indicate service circumstances (e.g., split/shared, wasted drug, professional/technical components) and linked to the patient’s oncology diagnosis and chemotherapy administration codes. Typical site of service: outpatient infusion center, hospital outpatient department, or inpatient infusion unit.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |